Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

Sponsor
Grupo Español Multidisciplinar de Melanoma
Study ID
NCT04184518
Phase
PHASE2
Status
Withdrawn

Conditions

  • Metastatic Cancer
  • Uveal Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cediranib Maleate — DRUG
    Cediranib 20mg, oral, 5 days on and 2 days off until disease progression
  • Durvalumab — DRUG
    Durvalumab 1500mg, intravenous, every 4 weeks until disease progression

Study Details

Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic or liver directed therapy.

Key Dates

Start date
May 31, 2020
Status verified
May 2020
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cediranib plus durvalumab

Primary Outcome Measure

Objective response rate by RECIST 1.1 [ Time Frame: 24 months after start of treatment ]

Related Studies